140 likes | 291 Views
INCOMPATIBLE LIVING DONOR KIDNEY TRANSPLANTATION What Choices? Lisa Burnapp Consultant Nurse Directorate of Nephrology, Transplantation and Urology Guy’s and St Thomas’ NHS Foundation Trust London, UK lisa.burnapp@gstt.nhs.uk. Our Responsibility. To optimise Patient outcome
E N D
INCOMPATIBLE LIVING DONOR KIDNEY TRANSPLANTATION What Choices? Lisa Burnapp Consultant Nurse Directorate of Nephrology, Transplantation and Urology Guy’s and St Thomas’ NHS Foundation Trust London, UK lisa.burnapp@gstt.nhs.uk
Our Responsibility To optimise • Patient outcome • Transplant outcome • Planning • Opportunity & choice • Use of kidneys • Donor safety & well-being • The health economy
The Challenge More • Patients • Choice & capability • Expectation • Complex • Ethnically diverse
Extended Criteria (High-Risk) Recipients ‘Recipients at a significantly higher risk of death, complications or graft failure because of pre-existing co-morbidity or immunological status’1 High-risk includes • Immunological/ABO incompatibility • The elderly • Significant co-morbidity • Primary disease 1 Guidelines for Living Donor Kidney Transplantation in High-Risk Adult Recipients, 2008 www.bts.org.uk
High-Risk Recipients: Our Approach • Living donation treatment of choice • All patients provided with information early • Evidence and/or lack of evidence shared with recipient and donor • Risk benefit analysis discussed • Tailored management plan agreed • Peer support
Who Makes the Choice? • Patient & family? • What is best for them • Healthcare professionals? • Most clinically effective • Outcome reporting • What is feasible/available • Local logistics/infrastructure • Financial constraints • Primary care Trusts/Commissioners? • Health economics • National Guidance (NICE)
Tailored Option Appraisal • Do nothing • Acceptable if recipient & donor informed of possible options • Paired/pooled donation • Antibody removal strategies (ABO/HLA) • Offer neither • Lack of equity
Paired/Pooled Donation • Compatible living donor transplant • Clinically more straightforward • Logistically challenging • Uncertainty about timing & ‘matchability’ • Donors & recipients unknown to one another • indirect donation
Antibody Removal Strategies (ABO/HLA) • More complex scenarios • ^ intervention (recipient) • ^ immunosuppression • Higher risk of failure • spectrum of risk • Time specific • Donor known to recipient • direct donation
Summary • Evolving field • Clinically challenging • Physically & psychologically demanding for patients & their families • Compatible transplantation always the preferred option • Outcomes encouraging